Difference between revisions of "Part:BBa K5384001:Design"
(→References) |
(→References) |
||
Line 16: | Line 16: | ||
===References=== | ===References=== | ||
− | + | 1.Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058. | |
− | + | 2.Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317. | |
− | + | ||
− | + | ||
− | + |
Revision as of 14:54, 29 September 2024
Vglycin (Vg)
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
Vglycin has excellent hypoglycemic effect.
Source
vglycin is a 37-amino-acid peptide derived from legumes.
References
1.Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058. 2.Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.